These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 33161038)

  • 1. A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFRβ exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model.
    Guo R; Yang Y; Zhang D; Du J; Zhu X; Liu Y; Yang F; Lin J
    Int J Pharm; 2021 Jan; 592():120037. PubMed ID: 33161038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
    Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
    Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7.
    Cao L; Li Q; Tong Z; Xing Y; Xu K; Yijia Wang J; Li W; Zhao J; Zhao L; Hong Z
    Int J Pharm; 2020 Jan; 574():118939. PubMed ID: 31836485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.
    Shinohara H; Morita S; Kawai M; Miyamoto A; Sonoda T; Pastan I; Tanigawa N
    J Surg Res; 2002 Feb; 102(2):169-77. PubMed ID: 11796015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
    Huang L; He H; Wang K; Ma X; Chen X; Chen W; Wang X; Jiang X; Feng M
    Biomed Pharmacother; 2022 Nov; 155():113659. PubMed ID: 36095959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxin IHP25-BT with low immunogenicity and off-target toxicity inhibits the growth and metastasis of trastuzumab-resistant tumor cells.
    Guo R; Zhang D; Zhang C; Yang Y; Liu H; Yang Y; Lin J
    Int J Pharm; 2021 Oct; 608():121081. PubMed ID: 34506924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
    Kioi M; Seetharam S; Puri RK
    Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma.
    Onda M; Bruland ØS; Pastan I
    Clin Orthop Relat Res; 2005 Jan; (430):142-8. PubMed ID: 15662316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand.
    Li Q; Li W; Xu K; Xing Y; Ding Y; Jing Z; Wang X; Hong Z
    Int J Pharm; 2021 Jun; 602():120647. PubMed ID: 33915185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.
    Mazor Y; Sachsenmeier KF; Yang C; Hansen A; Filderman J; Mulgrew K; Wu H; Dall'Acqua WF
    Sci Rep; 2017 Jan; 7():40098. PubMed ID: 28067257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
    Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
    Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.